Oncolytic Virus Vector Engineering for Systemic Tumor Spreading
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current oncolytic viruses lack effective mechanisms for enhancing intratumoral and intertumoral spreading, systemic delivery, tumor-specific replication, and immune evasion, limiting their therapeutic efficacy in cancer treatment.
Innovation Solution
Modified oncolytic viruses, such as those with modifications like deletions or mutations in genes like B5R and A52R, and the inclusion of exogenous nucleic acids coding for chemokine receptors and hyaluronidases, enhance intratumoral and intertumoral spreading, systemic delivery, and tumor-specific replication while promoting immune evasion.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If oncolytic viruses are used for cancer treatment, then tumor cells can be selectively infected and lysed, but the viruses lack effective mechanisms for enhancing intratumoral and intertumoral spreading, systemic delivery, and immune evasion
Solution Approach 1:
The virus is segmented into multiple functional components: deletions in specific genes (B5R, A52R) create functional segments that enhance spreading and immune evasion, while exogenous nucleic acid segments encode chemokine receptors and hyaluronidases for targeted delivery and matrix degradation. This segmentation allows independent optimization of each function.
Solution Approach 2:
The oncolytic virus is engineered as a composite biological system combining viral components (vaccinia virus backbone) with exogenous functional elements (chemokine receptors like CXCR4/CCR2, hyaluronidases like PH-20/HysA). This composite structure integrates multiple therapeutic functions into a single viral vector for enhanced efficacy.
2Reliability
If the virus genome is modified with deletions or mutations to enhance spreading and immune evasion, then therapeutic efficacy improves, but the complexity of viral engineering increases
Solution Approach 1:
Specific genes (B5R, A52R) are extracted or deleted from the viral genome to eliminate functions that limit spreading or trigger immune responses. This extraction simplifies the viral structure by removing unnecessary components while enhancing desired functions.
Solution Approach 2:
The viral genome is pre-modified with deletions and insertions of exogenous nucleic acids before virus production. This preliminary engineering of the genetic blueprint ensures that the resulting virus particles inherently possess enhanced spreading and immune evasion capabilities without requiring post-production modifications.
3Reliability
If exogenous nucleic acids coding for chemokine receptors and hyaluronidases are included, then systemic delivery and tumor-specific replication are enhanced, but the manufacturing process becomes more complex
Solution Approach 1:
Multiple functional elements (chemokine receptor genes, hyaluronidase genes, and viral genome) are merged into a single exogenous nucleic acid construct that is co-transfected with the viral backbone. This combining of functions into integrated genetic elements streamlines the manufacturing process compared to separate introduction of each component.
Solution Approach 2:
The exogenous nucleic acids are designed to be self-expressing within infected cells, automatically producing the chemokine receptors and hyaluronidases needed for enhanced delivery and spreading. The virus essentially manufactures its own enhancement tools during infection, reducing the need for external supplementation.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The modified oncolytic viruses exhibit enhanced intratumoral and intertumoral spreading, improved tumor-specific replication, and immune evasion, thereby improving therapeutic efficacy in cancer treatment.
Implementation Method 1
an exogenous nucleic acid that codes for a chemokine receptor, wherein expression of the chemokine receptor from the virus enhances systemic delivery of the virus
Implementation Method 2
a membrane associated protein that can be capable of degrading hyaluronan... the exogenous nucleic acid that codes for the membrane associated protein can code for a hyaluronidase
Implementation Method 3
enhance intratumoral and intertumoral spreading, systemic delivery, and tumor-specific replication
Data Source
AI summary
This disclosure provides a modified oncolytic virus that can contain modifications in the viral genome and exogenous nucleic acids coding for proteins. The modified oncolytic virus can be utilized as a platform vector for systemic delivery.